Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF ADMINISTRATION OF AN ANTI-CD5 PLUS IMMUNOCONJUGATE IN RHEUMATOID-ARTHRITIS - RESULTS OF 2 PHASE-II STUDIES
Autore:
STRAND V; LIPSKY PE; CANNON GW; CALABRESE LH; WIESENHUTTER C; COHEN SB; OLSEN NJ; LEE ML; LORENZ TJ; NELSON B; CUSH JJ; WOLFE F; FLEISCHMANN RM; KARR RM; KRICK GH; MEDSGER TA; RIGBY WFC; FOX DA; SWARTZ TJ; MULTZ CV; WEISMAN MH;
Indirizzi:
XOMA CORP,CORP COMMUN,2910 7TH ST BERKELEY CA 94710 METROPLEX CLIN RES CTR DALLAS TX 00000 UNIV CALIF SAN FRANCISCO,DEPT MED SAN FRANCISCO CA 94143 UNIV TEXAS,SW MED CTR DALLAS TX 75230 UNIV UTAH,DEPT MED SALT LAKE CITY UT 84112 UNIV UTAH,VET ADM MED CTR SALT LAKE CITY UT 84112 CLEVELAND CLIN EDUC FDN,DEPT RHEUMATOL CLEVELAND OH 44106 VANDERBILT UNIV,DIV RHEUMATOL & IMMUNOL NASHVILLE TN 37240 UCLA,SCH PUBL HLTH LOS ANGELES CA 00000 ARTHRITIS CTR WICHITA KS 00000 UNIV WASHINGTON,DEPT MED SEATTLE WA 98195 CEDAR MED CTR TACOMA WA 00000 UNIV PITTSBURGH PITTSBURGH PA 15260 DARTMOUTH COLL,HITCHCOCK MED CTR HANOVER NH 03756 UNIV MICHIGAN HOSP ANN ARBOR MI 48109 UNIV CHICAGO CHICAGO IL 60637 ARTHRITIS CARE CTR INC SAN JOSE CA 00000 UNIV CALIF SAN DIEGO SAN DIEGO CA 92103
Titolo Testata:
Arthritis and rheumatism
fascicolo: 5, volume: 36, anno: 1993,
pagine: 620 - 630
SICI:
0004-3591(1993)36:5<620:EOAOAA>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
TOTAL LYMPHOID IRRADIATION; THORACIC-DUCT DRAINAGE; LOW-DOSE METHOTREXATE; MONOCLONAL-ANTIBODY; PULSE METHOTREXATE; TRIAL; EFFICACY; DISEASE; PLACEBO; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
41
Recensione:
Indirizzi per estratti:
Citazione:
V. Strand et al., "EFFECTS OF ADMINISTRATION OF AN ANTI-CD5 PLUS IMMUNOCONJUGATE IN RHEUMATOID-ARTHRITIS - RESULTS OF 2 PHASE-II STUDIES", Arthritis and rheumatism, 36(5), 1993, pp. 620-630

Abstract

Objective. To evaluate the safety and activity of an immunoconjugate of ricin A chain and anti-CD5 monoclonal antibody (anti-CD5 IC), with and without concomitant methotrexate and/or azathioprine, in the treatment of rheumatoid arthritis (RA). Methods. Seventy-nine patients withactive RA were enrolled in 2 prospective open-label protocols. Results. Using composite criteria, response rates were 50-68% at 1 month and22-25% at 6 months. Transient depletion of CD3/CD5 T cells was observed on days 2 and 5 of treatment, with reconstitution on day 15 or day 29. Treatment-associated adverse effects were common but resolved rapidly without sequelae. Conclusion. These findings suggest activity of anti-CD5 IC in active RA and warrant confirmation in a multicenter randomized study (currently underway).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 06:59:57